Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 20, 2026Cancer Immunology Research

Abstract C008: NFIL3 emerges as a driver of CAR T cell dysfunction from integrated in vivo/in vitro CRISPR screen

View Full Paper
Ask AI
Bookmark
Share

Authors

NJNayan JainYSYuzhe ShiCMCelina May

Discussion

Loading...

Member takes

Overview

Identifies NFIL3 as a key regulator of CAR T cell function in a mouse model, suggesting it as a target for improved cancer therapies.

Key Points

  • The research aims to identify molecular regulators of CAR T cell dysfunction to enhance their efficacy in treating cancer.
  • Conducted a multi-parameter in vivo CRISPR screen targeting 400 transcription factors.
  • Used NALM6 mouse model for acute lymphoblastic leukemia with sequential tumor rechallenges.
  • Evaluated the function of candidate regulators in an in vitro chronic activation screen.
  • NFIL3 was identified as a negative regulator of CAR T cell function.
  • Genetic ablation of NFIL3 increased CAR T cell expansion and cytokine production.
  • NFIL3 disruption enhanced antitumor activity in various cancer models.

Cite This Study

Jain et al. (2026) studied this question.

synapsesocial.com/papers/6997f9b8ad1d9b11b345268bhttps://doi.org/10.1158/2326-6074.io2026-c008
View Full Paper
Ask AI
Bookmark
Share